J Zhang1, A S Puri2, M A Khan3, R P Goddeau1, N Henninger4. 1. From the Departments of Neurology (J.Z., N.H., R.P.G.). 2. Radiology (A.S.P.) Neurosurgery (A.S.P.). 3. Department of Neurology (M.A.K.), Warren Alpert Medical School of Brown University, Providence, Rhode Island. 4. From the Departments of Neurology (J.Z., N.H., R.P.G.) Psychiatry (N.H.), University of Massachusetts Medical School, Worcester, Massachusetts nils.henninger@umassmed.edu.
Abstract
BACKGROUND AND PURPOSE: Leukoaraiosis is a common finding among patients with ischemic stroke and has been associated with poor stroke outcomes. Our aim was to ascertain whether the severity of pre-existing leukoaraiosis is associated with outcome in patients with acute ischemic stroke who are treated with endovascular stroke therapy. MATERIALS AND METHODS: We retrospectively analyzed data from 129 consecutive, prospectively enrolled patients with stroke undergoing endovascular stroke therapy at a single tertiary care center between January 2006 and August 2013. Leukoaraiosis was assessed as supratentorial white matter hypoattenuation on admission head CT and graded as 0-2 (absent-to-moderate) versus 3-4 (severe) according to the van Swieten scale. We dichotomized the 90-day mRS into good (0-2 or return to baseline) versus poor (3-6) as the primary study outcome. Incremental multivariable logistic regression analyses were performed to identify independent predictors of a poor 90-day outcome. RESULTS: In all multivariable models, severe leukoaraiosis was independently (P < .05) associated with a poor outcome at 90 days (fully adjusted model: OR, 6.37; 95% CI, 1.83-12.18; P = .004). The independent association between leukoaraiosis and a poor outcome remained when the analysis was restricted to patients who were alive at discharge (n = 87, P < .05). Last, among patients who were alive at discharge, those with severe leukoaraiosis had significantly less frequent improvement on the mRS from discharge to 90 days compared with patients with absent-to-moderate leukoaraiosis (P = .034). CONCLUSIONS: The severity of pre-existing leukoaraiosis is independently associated with 90-day functional outcome in patients with stroke who underwent endovascular stroke therapy. These results highlight the need to further explore leukoaraiosis as a promising surrogate marker for poor outcome after endovascular stroke therapy to improve risk assessment, patient selection, and early prognostic accuracy.
BACKGROUND AND PURPOSE:Leukoaraiosis is a common finding among patients with ischemic stroke and has been associated with poor stroke outcomes. Our aim was to ascertain whether the severity of pre-existing leukoaraiosis is associated with outcome in patients with acute ischemic stroke who are treated with endovascular stroke therapy. MATERIALS AND METHODS: We retrospectively analyzed data from 129 consecutive, prospectively enrolled patients with stroke undergoing endovascular stroke therapy at a single tertiary care center between January 2006 and August 2013. Leukoaraiosis was assessed as supratentorial white matter hypoattenuation on admission head CT and graded as 0-2 (absent-to-moderate) versus 3-4 (severe) according to the van Swieten scale. We dichotomized the 90-day mRS into good (0-2 or return to baseline) versus poor (3-6) as the primary study outcome. Incremental multivariable logistic regression analyses were performed to identify independent predictors of a poor 90-day outcome. RESULTS: In all multivariable models, severe leukoaraiosis was independently (P < .05) associated with a poor outcome at 90 days (fully adjusted model: OR, 6.37; 95% CI, 1.83-12.18; P = .004). The independent association between leukoaraiosis and a poor outcome remained when the analysis was restricted to patients who were alive at discharge (n = 87, P < .05). Last, among patients who were alive at discharge, those with severe leukoaraiosis had significantly less frequent improvement on the mRS from discharge to 90 days compared with patients with absent-to-moderate leukoaraiosis (P = .034). CONCLUSIONS: The severity of pre-existing leukoaraiosis is independently associated with 90-day functional outcome in patients with stroke who underwent endovascular stroke therapy. These results highlight the need to further explore leukoaraiosis as a promising surrogate marker for poor outcome after endovascular stroke therapy to improve risk assessment, patient selection, and early prognostic accuracy.
Authors: Simon Jung; Marie Luise Mono; Oliver Findling; Urs Fischer; Aekaterini Galimanis; Anja Weck; Gian Marco De Marchis; Pietro Ballinari; Jan Gralla; Caspar Brekenfeld; Gerhard Schroth; Marcel Arnold; Heinrich P Mattle; Marwan El-Koussy Journal: J Neurol Date: 2012-01-17 Impact factor: 4.849
Authors: Edward C Jauch; Jeffrey L Saver; Harold P Adams; Askiel Bruno; J J Buddy Connors; Bart M Demaerschalk; Pooja Khatri; Paul W McMullan; Adnan I Qureshi; Kenneth Rosenfield; Phillip A Scott; Debbie R Summers; David Z Wang; Max Wintermark; Howard Yonas Journal: Stroke Date: 2013-01-31 Impact factor: 7.914
Authors: S Koton; Y Schwammenthal; O Merzeliak; T Philips; R Tsabari; D Orion; R Dichtiar; D Tanne Journal: Eur J Neurol Date: 2008-12-09 Impact factor: 6.089
Authors: Joseph P Broderick; Yuko Y Palesch; Andrew M Demchuk; Sharon D Yeatts; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Frank L Silver; Rüdiger von Kummer; Carlos A Molina; Bart M Demaerschalk; Ronald Budzik; Wayne M Clark; Osama O Zaidat; Tim W Malisch; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Renée H Martin; Lydia D Foster; Thomas A Tomsick Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245
Authors: Zhong-Song Shi; Yince Loh; David S Liebeskind; Jeffrey L Saver; Nestor R Gonzalez; Satoshi Tateshima; Reza Jahan; Lei Feng; Paul M Vespa; Sidney Starkman; Noriko Salamon; J Pablo Villablance; Latisha K Ali; Bruce Ovbiagele; Doojin Kim; Fernando Viñuela; Gary R Duckwiler Journal: Stroke Date: 2012-05-10 Impact factor: 7.914
Authors: Michela Simoni; Linxin Li; Nicola L M Paul; Basil E Gruter; Ursula G Schulz; Wilhelm Küker; Peter M Rothwell Journal: Neurology Date: 2012-09-05 Impact factor: 9.910
Authors: E A Mistry; A M Mistry; T Mehta; N Arora; A K Starosciak; F D L R La Rosa; J E Siegler; S E Kasner; R Chitale; M Fusco; M Froehler; S Yaghi; M Schrag; P Khatri Journal: AJNR Am J Neuroradiol Date: 2020-03-12 Impact factor: 3.825
Authors: Y Mayasi; R P Goddeau; M Moonis; B Silver; A H Jun-O'Connell; A S Puri; N Henninger Journal: AJNR Am J Neuroradiol Date: 2017-11-23 Impact factor: 3.825
Authors: Abdul Ghani Mikati; Max Mandelbaum; Shweta Sapnar; Ajit S Puri; Brian Silver; Richard P Goddeau; Diogo C Haussen; Majaz Moonis; Adalia H Jun-O'Connell; Nils Henninger Journal: Transl Stroke Res Date: 2019-04-12 Impact factor: 6.829
Authors: Christoph Johannes Griessenauer; David McPherson; Andrea Berger; Ping Cuiper; Nelson Sofoluke; Matthew D Adams; Saran Kunaprayoon; Ramin Zand; Jiang Li; Vida Abedi; Oded Goren; Clemens M Schirmer; Kathleen Donahue; Marco Nardin; Anne-Karin Giese; Markus D Schirmer; Natalia S Rost; Philipp Hendrix Journal: Cerebrovasc Dis Date: 2020-07-21 Impact factor: 2.762
Authors: Zimbul Albo; Jose Marino; Muhammad Nagy; Dilip K Jayaraman; Muhammad U Azeem; Ajit S Puri; Nils Henninger Journal: J Neurointerv Surg Date: 2020-05-15 Impact factor: 5.836